A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.

导出 OA

翻译打印收藏纠错

作者： Bradley J,Monk ^[1] ; James T,Kauderer ^[2] ; Katherine M,Moxley ^[3] ; Albert J,Bonebrake ^[4] ; Summer B,Dewdney ^[5] ; Angeles Alvarez,Secord ^[6] ; Frederick R,Ueland ^[7] ; Carolyn M,Johnston ^[8] ; Carol,Aghajanian ^[9]

作者单位： Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph Hospital, Phoenix, AZ, USA. Electronic address: Bradley.Monk@usoncology.com. ^[1] NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park, Buffalo, NY, USA. Electronic address: jkauderer@gogstats.org. ^[2] University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: katherine-moxley@ouhsc.edu. ^[3] Cancer Research for the Ozarks-Cox Health. Ferrell Duncan Clinic GYN-ONC, Springfield, MO 65807, USA. Electronic address: albert.bonebrake@coxhealth.com. ^[4] Rush University Medical Center, Chicago, IL 60612, USA. Electronic address: summer_dewdney@rush.edu. ^[5] Duke University Medical Center, Duke Cancer Institute, Durham, NC, USA. Electronic address: angeles.secord@duke.edu. ^[6] University of Kentucky, Lexington, KY 40536, USA. Electronic address: fuela0@uky.edu. ^[7] University of Michigan Health System-Cancer Center, Ann Arbor, MI, USA. Electronic address: johnstob@med.umich.edu. ^[8] Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA. Electronic address: aghajanc@mskcc.org. ^[9]

关键词 Clinical trial Elesclomol Ovarian cancer